Abstract
The medical therapy of reflux esophagitis consists of modifications of the patients's lifestyle and antacids, alginic acid or both (phase I). Phase II medications include drugs that suppress acid/peptic activity (antacid/alginate, H2-receptor blockers, cimetidine, ranitidine, famotidine), drugs that enhance motility (metoclopramide, domperidone) and drugs that coat and increase mucosal protection (sucralfate). Combinations of H2-receptor blockers and motility stimulating drugs have not been very effective. Overall the results of medical therapy of reflux esophagitis are suboptimal.
MeSH terms
-
Alginates / therapeutic use
-
Aluminum Hydroxide / therapeutic use
-
Antacids / therapeutic use
-
Bicarbonates / therapeutic use
-
Combined Modality Therapy
-
Dilatation
-
Domperidone / therapeutic use
-
Drug Combinations / therapeutic use
-
Esophagitis, Peptic / drug therapy
-
Gastroesophageal Reflux / drug therapy*
-
Histamine H2 Antagonists / therapeutic use
-
Humans
-
Metoclopramide / therapeutic use
-
Peristalsis / drug effects
-
Silicic Acid / therapeutic use
-
Sodium Bicarbonate*
-
Sucralfate / therapeutic use
Substances
-
Alginates
-
Antacids
-
Bicarbonates
-
Drug Combinations
-
Histamine H2 Antagonists
-
Silicic Acid
-
Sucralfate
-
Domperidone
-
Aluminum Hydroxide
-
alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination
-
Sodium Bicarbonate
-
Metoclopramide